Smulkiųjų ląstelių plaučių vėžio imunoterapija
2021
Despite permanent scientific activity and research, limited progress has been made in more than two decades in the treatment of small-cell lung cancer (SCLC). The prognosis of SCLC remains poor. SCLC is a very immunogenic tumor with high somatic mutation numbers, immunosuppressive status. According to the recently published clinical trials, two immune-checkpoint inhibitors – atezolizumab and durvalumab, significantly prolong overall survival in this disease without additional safety concerns.
Keywords:
- Correction
- Source
- Cite
- Save
- Machine Reading By IdeaReader
0
References
0
Citations
NaN
KQI